Table 2.

Summary of engraftment rates of PDX tumors

Tumor type	Mice strain	Implantation site	Engraftment rate	References
Breast cancer	Nude	Subcutaneous	13%	Marangoni et al., 2007
	NOD scid	Mammary fat pad	27%	DeRose et al., 2011
	scid/Beige, NSG	Mammary fat pad	19–21%	Zhang et al., 2013
	NOD scid	Humanized mammary fat pad	13%	Li et al., 2013
Colorectal cancer	NOD scid	Subcutaneous	87%	Bertotti et al., 2011
	Nude	Subcutaneous	64%	Julien et al., 2012
	Nude	Orthotopic	89%	Aytes et al., 2012
Head and neck cancer (squamous cell carcinoma)	NSG	Subcutaneous	85%	Kimple et al., 2013
	Nude	Subcutaneous	54%	Keysar et al., 2013
Medulloblastoma	Rag2 scid	Orthotopic	52%	Zhao et al., 2012
Non-small cell lung cancer	NOD scid	Subcutaneous	25%	Fichtner et al., 2008
	NOD scid	Renal capsule	90%	Dong et al., 2010
Pancreatic cancer (ductal adenocarcinoma)	Nude	Subcutaneous	61%	Garrido-Laguna et al., 2011
	Nude	Orthotopic	62%	Reyes et al., 1996
	ICR scid	Subcutaneous	67%	Mattie et al., 2013
Uveal melanoma	NOD scid	Subcutaneous	28%	Némati et al., 2010